After hours

Sarepta Therapeutics, Inc.

SRPT · Nasdaq

Analyst Consensus

Hold

21 analysts

$18

Current

—

Low

$20

Average

—

High

Average target implies +11.23% versus the current price.

Analyst Ratings Synthesis

The supplied consensus field is unknown, but third-party pages show materially different snapshots: StockAnalysis reports 24 analysts with an average Hold rating and a $22.26 target, while ChartMill cites 33 analysts and a $25.25 average target. Reported target dispersion is otherwise unavailable because the supplied figures do not include comparable low and high estimates. H.C. Wainwright is the most explicitly bearish named firm, reaffirming Sell; Ritu Baral is less negative with Hold and a $17 target. Simply Wall St says the average target was trimmed by $1 to $19, indicating downward revision pressure. The substantive disagreement centers on whether revenue growth can offset worsening profitability and operating risk.

Rating Actions

No individual rating actions have been captured for SRPT yet. Consensus figures above come from Nasdaq's aggregate feed.

Rating actions are extracted from published reporting. Each row links to its source.

Research Reports

Links to freely available third-party research. Outlook labels are our classification of each article's stance, not a rating of our own.

Covering Firms

B OF A GLBL RES

BAIRD R W

BARCLAYS CAPITA

CANTOR FITZGERA

CITIGROUP

DEUTSCHE BK SEC

EVERCORE ISI

GOLDMAN SACHS

JP MORGAN SECUR

LEERINK PARTNRS

MIZUHO SECURITI

MORGAN STANLEY

NEEDHAM & CO.

OPPENHEIMER HLD

RAYMOND JAMES

RBC CAPITAL

TD COWEN

UBS

WEDBUSH SECURIT

WILLIAM BLAIR

ZACKS RESEARCH

Symbol: SRPT
Type: Stock
Sector: Health Care
Industry: Biotechnology: Pharmaceutical Preparations
Country: North America
Exchange: Nasdaq

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold a leadership position in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases.

Key Issues

Bullish view

Revenue increased to $1.9 billion in FY2025 from $1.8 billion in FY2024, supporting the case that Sarepta has a growing commercial base.

Bearish view

Net income deteriorated from a $0.2 billion profit to a $0.7 billion loss, showing that higher revenue has not translated into sustained profitability.

Analyst Consensus

See all

Hold

21 analysts

$18

Current

—

Low

$20

Average

—

High

Average target implies +11.23% versus the current price.

Earnings History

BeatMissNo estimate

Sarepta Therapeutics, Inc.

Analyst Consensus

Analyst Ratings Synthesis

Rating Actions

Research Reports

Covering Firms

Peers